OOIR: Observatory of International Research

Papers

(The H4-Index of Thoracic Cancer is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Curcumin induces ferroptosis in non‐small‐cell lung cancer via activating autophagy	98
Trends in the incidence and survival of patients with esophageal cancer: A SEER database analysis	85
Quercetin induces pro‐apoptotic autophagy via SIRT1/AMPK signaling pathway in human lung cancer cell lines A549 and H1299 in vitro	71
A meta‐analysis of contrast‐enhanced spectral mammography versus MRI in the diagnosis of breast cancer	48
Circ‐RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR‐140‐5p	45
LncRNA HOTAIR enhances breast cancer radioresistance through facilitating HSPA1A expression via sequestering miR‐449b‐5p	42
Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients	41
Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients	40
Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series an	39
Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions	38
Circular RNA CirCHIPK3 promotes cell proliferation and invasion of breast cancer by sponging miR‐193a/HMGB1/PI3K/AKT axis	37
Genomic characteristics and drug screening among organoids derived from non‐small cell lung cancer patients	36
CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)	36
Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040	34
Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events	33
circ_0007385 served as competing endogenous RNA for miR‐519d‐3p to suppress malignant behaviors and cisplatin resistance of non‐small cell lung cancer cells	32
Impact of COVID‐19 pandemic on lung cancer treatment scheduling	31
Expression and role of p16 and GLUT1 in malignant diseases and lung cancer: A review	31
Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer	30
Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD‐1 antibody	29
Propofol suppresses lung cancer tumorigenesis by modulating the circ‐ERBB2/miR‐7‐5p/FOXM1 axis	28
miR‐21‐5p/SMAD7 axis promotes the progress of lung cancer	27
Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer	27
Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in EGFR mutant non‐small cell lung cancer cells	27
Circ_0038467 regulates lipopolysaccharide‐induced inflammatory injury in human bronchial epithelial cells through sponging miR‐338‐3p	27

Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study